Patent intelligence · US
US 10071150
Immunity enhancing therapeutic vaccine for HPV and related diseases
Immunity enhancing therapeutic vaccine for HPV and related diseases
Patent details — US 10071150
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 11, 2018
- Expiration
- Sep 6, 2038
- Applicant
- MYGT Biopharmaceutical LLC
- Claims
- 17
- CPC classes
- A61K, A61K2039/6031, A61K2039/6043, A61K39/12
Quick answer
US 10071150 (Immunity enhancing therapeutic vaccine for HPV and related diseases) is held by MYGT Biopharmaceutical LLC. Status: granted. Granted Sep 11, 2018. Expires Sep 6, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MYGT Biopharmaceutical LLC
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K2039/6031, A61K2039/6043, A61K39/12, A61K39/39, A61P
Frequently asked questions
What is US patent 10071150?
US 10071150 (Immunity enhancing therapeutic vaccine for HPV and related diseases) is held by MYGT Biopharmaceutical LLC. Status: granted. Granted Sep 11, 2018. Expires Sep 6, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10071150?
MYGT Biopharmaceutical LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 10071150 expire?
Our index shows an expiration date of Sep 6, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.